RVMD·Nasdaq·US
Revolution Medicines
Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies against RAS-driven cancers. Its pipeline centers on RAS(ON) inhibitors and related companion inhibitors, with no approved commercial products disclosed in the available materials.
Recent Activity
Updated Sep 24, 2026
–Revolution Medicines received U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in combination with chemotherapy for first-line metastatic pancreatic cancer.
–This marks the company's third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.